Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Fluence Corporation: Further Progress In China

Published 09/05/2019, 06:24 AM
Updated 07/09/2023, 06:31 AM
FLC
-
Fluence Revenue

Fluence Corporation Ltd (ASX:FLC) has signed a Memorandum of Understanding (MoU) to deliver over 250 Aspiral wastewater treatment units to a Chinese partner (Kaitian) and is establishing a local final assembly facility in Yiyang to meet this demand. This is its second high-volume contract in China and, following the recent SUBRE order, provides evidence of both the significant potential of this market and the progress Fluence is making. With a market cap of c US$150m, the full value of this opportunity is not currently reflected in Fluence’s valuation, in our view.

Fluence has announced an MoU with Kaitian, its local partner in Hunan province in China, to supply Aspiral L4 units to meet a total capacity of 40,000m3/day by the end of 2021. The MoU is still subject to signing binding purchase orders, but builds on its previous pilot deals with Kaitian. The potential revenue impact is not stated, but assuming each Aspiral unit treats c 150m3/day and sells for US$70k, we estimate that the total agreement, recognised over three years, could involve supplying more than 250 Aspiral units and generate revenue of over US$18m. The first products are due to be shipped before the end of 2019. We make no changes to our forecasts at this stage.

To supply these units, Fluence has also signed a letter of intent with the local government to establish an Aspiral production facility in Yiyang with an annual capacity of 120 L4 units. This final assembly facility will be additional to Fluence’s Changzhou factory, which will remain focused on producing its proprietary MABR modules.

We highlighted the potential of China in both our China Contract catalyst and initiation notes. We believe that the initiative to upgrade rural wastewater treatment is a US$4.7bn opportunity and Fluence’s proprietary MABR technology (on which Aspiral is based) is a uniquely cost-effective solution to meeting China’s exacting Class 1A effluent standards.

Business description

Fluence is a global supplier of water and wastewater treatment solutions. Its decentralised products provide municipal customers with ‘plug and play’ solutions that are quicker to deploy and substantially cheaper than traditional alternatives.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.